Hansa Biopharma: Expanding launch foundation - Redeye

The German reimbursement agreement and expanding hospital financing support is distinctly positive. Over the next 12-24 months, we can expect a gradual expansion for the use of Idefirix across European leading centers, and this is an essential step in the right direction.

Länk till analysen i sin helhet: https://www.redeye.se/research/836412/hansa-biopharma-expanding-launch-foundation?utm_source=finwire&utm_medium=RSS